Newsletter Tool

Editor’s Note: Vote now in #FierceMadness: The Best Biotech Name Tournament! Polls close at 12:01 a.m. on March 22.

Today’s Big News

Mar 21, 2024

Boundless Bio eyes $88M offering as spring biotech IPO market blooms

Innate drops monotherapy plans for lacutamab in one type of lymphoma after hold lift

Investors fund Prometheus team's 'unfinished business' with $400M for new inflammatory biotech Mirador

Fierce Biotech Fundraising Tracker '24: Mirador makes money moves with $400M series A; Capstan circles up $175M

Featured

Boundless Bio eyes $88M offering as spring biotech IPO market blooms

By James Waldron

Boundless Bio’s announcement earlier this month of plans to go public was a sign that the biotech IPO window hadn’t slammed shut after a flurry of offerings at the start of the year.

Innate drops monotherapy plans for lacutamab in one type of lymphoma after hold lift

By James Waldron

Just two months after the FDA lifted a clinical hold on trials of Innate Pharma’s lymphoma drug, the biotech has now dropped plans to pursue the anti-KIR3DL2 antibody as a monotherapy for a specific form of that cancer.

Investors fund Prometheus team's 'unfinished business' with $400M for new inflammatory biotech Mirador

By Annalee Armstrong

A brand-new biotech called Mirador Therapeutics has emerged from the team behind Prometheus Biosciences with a massive $400 million series A funding round—the biggest of 2024 so far.

Fierce Biotech Fundraising Tracker '24: Mirador makes money moves with $400M series A; Capstan circles up $175M

By Gabrielle Masson,Annalee Armstrong,Max Bayer

Welcome to Fierce Biotech's Fundraising Tracker, 2024's version.

Johnson & Johnson accuses former employee of taking thousands of files to new role at Pfizer

By Zoey Becker

The company is accusing former employee Andrew Brackbill of downloading thousands of confidential strategy-related files before leaving for rival Pfizer.

Nvidia inks tie-ups with Abridge, GE HealthCare and Microsoft as it expands its footprint in healthcare AI

By Heather Landi

The global computing powerhouse inked collaborations with Abridge, Microsoft, GE HealthCare and Hippocratic AI to to expand its generative AI capabilities into healthcare and life sciences.

Merck’s Lynparza-Keytruda combo sputters in 2nd lung cancer trial. Will an ADC pairing work instead?

By Angus Liu

Merck’s attempt to use Lynparza to boost Keytruda in metastatic non-small cell lung cancer has come up short with a second pivotal trial failure.

Fierce podcasts

Don’t miss an episode

'The Top Line': Inclusivity in psoriasis trials with Takeda

In this episode of 'The Top Line,' Fierce Biotech Senior Editor Annalee Armstrong interviews Karen Correa, Ph.D., from Takeda, discussing the crucial need for pharmaceutical companies to prioritize diversity in clinical trials.

'Podnosis': Why are some failing hospitals such appealing investments?

'The Top Line': Fierce Medtech's Fierce 15

Resources

Whitepaper

Pediatric Clinical Trials: Considerations for Enrollment and Retention

Explore the nuanced approaches necessary for successful pediatric drug development.

CNS Market Outlook, 2024

This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment.

Presented by Blue Matter, strategic consultants in the life sciences